



Press release x June 2026

## **Mathias Skalmstad new CFO at Diamyd Medical**

Diamyd Medical is pleased to announce that Mathias Skalmstad will take up the position of Chief Financial Officer at Diamyd Medical as early as July 1st, 2026.

"With my extensive experience from both listed companies and life sciences, I look forward to contributing to maximizing shareholder value for Diamyd moving forward," says Mathias Skalmstad.

Anders Essen-Möller, CEO of the Company, comments: "It is very satisfying that we have managed to recruit such a competent and experienced CFO as Mathias to Diamyd Medical on such short notice. I very much look forward to working with him."

### **About Diamyd Medical**

Diamyd Medical is a Swedish biotechnology company focused on precision medicine approaches for type 1 diabetes and biological manufacturing. The Company has established a facility for manufacturing of biological products in Umeå, Sweden. Diamyd Medical's B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser.

### **For further information, please contact:**

Anders Essen-Möller, CEO

Phone: +46 705 51 06 79

E-mail: [anders.essen-moller@diamyd.com](mailto:anders.essen-moller@diamyd.com)

### **Diamyd Medical AB (publ)**

Box 7349, SE-103 90 Stockholm, Sweden. Phone: +46 8 661 00 26

E-mail: [info@diamyd.com](mailto:info@diamyd.com) Org. nr: 556242-3797 Website: <https://www.diamyd.com>

The information was provided by the contact person above, for publication on 08:30 CET, June 25, 2026.